{"id":"NCT03197766","sponsor":"BioMarin Pharmaceutical","briefTitle":"A Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia","officialTitle":"A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-12-12","primaryCompletion":"2019-10-30","completion":"2019-10-30","firstPosted":"2017-06-23","resultsPosted":"2022-03-02","lastUpdate":"2022-03-02"},"enrollment":121,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Achondroplasia"],"interventions":[{"type":"DRUG","name":"BMN 111","otherNames":["Vosoritide","Modified recombinant human C-type natriuretic peptide"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Active BMN 111","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The intent and design of this Phase 3 study is to assess BMN 111 as a therapeutic option for the treatment of children with Achondroplasia.","primaryOutcome":{"measure":"Change From Baseline in Annualized Growth Velocity (AGV) at Week 52","timeFrame":"At Baseline and Week 52","effectByArm":[{"arm":"BMN 111 - 15 μg/kg","deltaMin":1.71,"sd":null},{"arm":"Placebo","deltaMin":0.13,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"< 0.0001"}]},"eligibility":{"minAge":"5 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":18},"locations":{"siteCount":24,"countries":["United States","Australia","Germany","Japan","Spain","Turkey (Türkiye)","United Kingdom"]},"refs":{"pmids":["39740666","39305160","38649657","34431071"],"seeAlso":["https://ghr.nlm.nih.gov/condition/achondroplasia","https://rarediseases.info.nih.gov/diseases/8173/achondroplasia","https://clinicaltrials.gov/ct2/info/fdalinks"]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":60},"commonTop":["Injection site erythema","Injection site reaction","Nasopharyngitis","Headache","Injection site swelling"]}}